(Reuters) – The U.S. Food and Drug administration said on Thursday that certain of the insulin pump, from Medtronic Plc, have been recalled due to a potential risk that they may be compromised.
The drug regulator said it is not aware of any confirmed reports of an injury to the patient due to the potential risks of cyber security.
Medtronic has identified about 4,000 patients, which is possible with the use of insulin pumps, which are particularly vulnerable to this problem, the agency said.
The FDA, in March, said a cyber security vulnerabilities have been identified in Medtronic’s implantable cardiac devices, hospital coders, and home monitoring.
Reporting Uday Sampath, Bengaluru; Editing by Arun Koyyur